Is there a test for Alzheimer’s disease for an individual with a family history of dementia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, Testing is Available and Should Be Pursued Through Proper Channels Based on Your Family History Pattern

If you have a family history of dementia, genetic testing may be appropriate, but the type of test and whether it's recommended depends critically on the pattern of dementia in your family—specifically whether it suggests early-onset autosomal dominant disease versus late-onset familial or sporadic disease. The testing must occur within the context of formal genetic counseling, not through direct-to-consumer services 1.

Understanding Your Family History Pattern First

Before any testing, you need a detailed 3-generation family history documenting 1:

  • Age of onset of dementia symptoms in affected relatives
  • Type of dementia diagnosed (if known)
  • Current ages or ages at death of both affected and unaffected relatives
  • Causes of death
  • Medical records to confirm diagnoses when possible

This assessment determines whether your family pattern suggests:

Autosomal Dominant Pattern (Rare, <5% of cases)

  • Disease in ≥3 individuals across ≥2 generations
  • Two affected individuals are first-degree relatives of the third
  • Usually involves early-onset AD (symptoms before age 65)
  • 50% risk of inheriting the mutation if a parent is affected 1

Familial Pattern (15-25% of cases)

  • Multiple affected individuals who are third-degree relatives or closer
  • Most commonly late-onset disease
  • Increased risk but not 50% 1

Sporadic Pattern (75% of cases)

  • Isolated case or cases separated by >3 degrees of relationship
  • Lowest genetic risk 1

Testing Recommendations Based on Family Pattern

For Autosomal Dominant Families (Early-Onset)

Genetic testing for causative genes (PSEN1, PSEN2, APP) should be offered when 1:

  • A symptomatic individual has early-onset AD with family history of dementia
  • Family shows autosomal dominant pattern with ≥1 case of early-onset disease
  • A relative has a known mutation in PSEN1, PSEN2, or APP

Critical protocol requirements 1:

  • Test an affected family member first whenever possible—this maximizes informativeness
  • If no affected member is available and you're asymptomatic but still want testing, you must undergo counseling following International Huntington Association protocols
  • Testing must occur with formal genetic counseling by an expert
  • Results require interpretation using the Alzheimer Disease & Frontotemporal Dementia Mutation Database

Important caveats: Mutations are only identified in 40-80% of families with apparent autosomal dominant patterns, meaning a negative result doesn't eliminate risk 1. Age of onset can vary by >20 years within the same family carrying the same mutation 1.

For Familial or Sporadic Patterns (Late-Onset)

APOE genetic testing is NOT clinically recommended 1. Here's why:

  • Limited clinical utility and poor predictive value
  • The APOE ε4 allele increases risk but is neither necessary nor sufficient for developing AD
  • Approximately 50-70% of people with AD carry ≥1 ε4 allele, but many ε4 carriers never develop AD 1
  • Direct-to-consumer APOE testing is specifically not advised 1

However, if you insist on APOE testing despite counseling against it, it may be considered at the clinician's discretion, but only with 1:

  • Formal genetic counseling by a qualified expert
  • Following Huntington disease genetic testing guidelines
  • Exploration of your motives and how results would impact your quality of life
  • Discussion of potential genetic discrimination issues

New Blood-Based Biomarker Testing (2024 Update)

For symptomatic patients aged ≥55 years in primary care, blood-based biomarker (BBM) tests are now recommended as a triage tool to determine if further confirmatory testing (amyloid PET or CSF) is warranted 2. This represents a significant advance but:

  • These are for diagnostic purposes in symptomatic patients, not predictive testing in asymptomatic individuals
  • Results must be interpreted alongside thorough medical history and cognitive assessment
  • Certain conditions (obesity, chronic kidney disease) and medications (secubitril/valsartan) can affect biomarker interpretation 2

Absolute Requirements for Any Genetic Testing

All genetic testing for AD must occur with 1:

  • In-person or videoconference genetic counseling by someone with AD genetics expertise
  • For symptomatic patients: counseling in the presence of a legal guardian or family member
  • For asymptomatic patients: protocol based on Huntington disease guidelines
  • Never through direct-to-consumer services

Pediatric testing should not occur, and prenatal testing is not advised if continuing the pregnancy 1.

What You Should Know About Risk

  • General population lifetime risk: 10-12% in a 75-80 year lifespan 1
  • First-degree relatives of affected individuals have increased risk, but precise estimates vary
  • Currently, there are no proven pharmacologic or lifestyle interventions that reduce AD risk or stop progression 1—this is a critical point for informed decision-making

Common Pitfalls to Avoid

  1. Pursuing direct-to-consumer APOE testing—this bypasses essential counseling and has limited clinical value
  2. Assuming a negative genetic test eliminates risk—many genes remain unidentified
  3. Testing without understanding the psychological and family implications—results affect not just you but your relatives' perception of their own risk
  4. Expecting actionable prevention strategies—currently, genetic information doesn't change management for asymptomatic individuals in most cases

Bottom Line Algorithm

Start here: Obtain detailed 3-generation family history → Consult genetic counselor specializing in AD

If early-onset autosomal dominant pattern: Test affected family member first for PSEN1/PSEN2/APP mutations → If positive, you can pursue predictive testing with appropriate counseling

If late-onset familial/sporadic pattern: APOE testing not recommended; focus on general risk counseling and monitoring

If you're symptomatic: Blood-based biomarkers now available as triage tool (age ≥55) → confirmatory testing if positive 2

The emergence of disease-modifying therapies makes accurate diagnosis increasingly important 2, but this applies to symptomatic patients, not asymptomatic predictive testing in most family patterns.

References

Related Questions

In an elderly patient with Alzheimer’s disease who is sleeping 12–14 hours per day and has poor oral intake, why is a positron emission tomography (PET) scan preferred over a computed tomography (CT) scan for assessing dementia severity and progression?
What evidence links Alzheimer's dementia to a genetic predisposition?
In an 80-year-old patient with Alzheimer disease experiencing sundowning, what medication regimen can be used to manage the symptoms?
What is the sleep diagnosis for a middle‑aged patient with early‑onset Alzheimer’s disease who has an irregular sleep‑wake cycle, withdrawal, confusion, aphasia, increased muscle tone, and temporal‑lobe dysfunction on PET scan?
What is the best imaging modality for diagnosing Alzheimer's disease (AD)?
Do finasteride or dutasteride increase breast cancer risk in women, and is a personal or first-degree family history of breast cancer a contraindication to using these 5‑alpha‑reductase inhibitors for female pattern hair loss?
How should respiratory fibrosis that develops after durvalumab therapy be managed?
What are the differential diagnoses for a patient with markedly elevated total bilirubin with direct hyperbilirubinemia, thrombocytopenia, fever, chills, and acute urinary retention?
What treatments are effective for fragile, atrophic skin that tears easily?
Can I take dronabinol 5 mg twice daily together with mirtazapine (Remeron) 15 mg at bedtime?
What does DLMO (Dim Light Melatonin Onset) stand for?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.